Molinalogo

Measure

2022

2023

Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

74.20%

70.09%

64.90%

Annual Dental Visits (ADV)

NB

NB

54.60%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

42.80%

49.97%

46.74%

Appropriate Testing for Pharyngitis (CWP)

33.72%

35.00%

77.56%

Appropriate Treatment for Upper Respiratory Infection (URI)

92.01%

93.09%

93.08%

Asthma Medication Ratio (AMR) Total

59.49%

61.84%

69.41%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB)

44.30%

54.12%

66.19%

Blood Pressure Control (<140/90) for Patients With Diabetes (BPD)

59.12%

63.26%

68.61%

Breast Cancer Screening (BCS)

51.27%

51.83%

55.25%

Cervical Cancer Screening (CCS)

57.66%

51.09%

59.85%

Childhood Immunization Status (CIS) Combination #10

34.55%

33.33%

35.04%

Chlamydia Screening in Women (CHL) Total

62.98%

61.48%

61.07%

Controlling High Blood Pressure (CBP)

54.99%

58.64%

65.45%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

82.92%

80.53%

80.86%

Eye Exam for Patients With Diabetes (EED)

52.55%

53.04%

56.20%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

3.47%

17.85%

27.73%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

7.84%

28.36%

46.35%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

NB

16.94%

41.03%

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total

8.3%

16.67%

37.31%

Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase

41.41%

46.26%

57.90%

Hemoglobin A1c Control for Patients With Diabetes (HBD) HbA1c Control (<8%)

51.09%

56.45%

55.72%

Immunizations for Adolescents (IMA) Combination #2

33.33%

32.91%

38.93%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

6.77%

8.46%

16.94%

Kidney Health Evaluation for Patients with Diabetes (KED)

53.25%

48.18%

38.80%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Blood Glucose and Cholesterol Testing Total

0.00%

40.79%

39.01%

Pharmacotherapy for Opioid Use Disorder (POD) Total

19.23%

21.51%

31.93%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

64.66%

65.61%

75.79%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

86.89%

86.07%

86.96%

Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years

93.61%

86.88%

≤ 92.72%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

85.40%

84.18%

86.86%

Prenatal and Postpartum Care (PPC) Postpartum Care

78.35%

82.00%

80.78%

Prenatal Immunization Status (PRS) Combination Rate

24.15%

22.97%

25.81

Risk of Continued Opioid Use (COU) 31-Day Total

2.73%

2.74%

≤ 2.45%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

79.40%

55.46%

81.64%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

74.47%

83.88%

73.63%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

71.78%

69.49%

67.07%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

68.31%

82.00%

70.37%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

NA

29.46%

63.89%

Use of Imaging Studies for Low Back Pain (LBP)

74.83%

73.36%

75.44%

Use of Opioids at High Dosage (HDO)

5.27%

2.09%

≤ 2.19%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

1.47%

0.17%

≤ 0.87%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

84.91%

82.97%

83.21%